Estimation of two real-time RT-PCR assays for quantitation of hepatitis C virus RNA during PEG-IFN plus ribavirin therapy by HCV genotypes and IL28B genotype

Miyagi, Yugo; Nomura, Hideyuki; Yamashita, Nobuyuki; Tanimoto, Hironori; Ito, Kiyoaki; Masaki, Naohiko; Mizokami, Masashi; Shibuya, Tsunefumi

doi:10.1007/s10156-012-0452-1

Cited by 3 publications

(2 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Novel methods for quantifying HCV RNA include two major assays, CAP/CTM HCV Test version 2.0 and ART HCV assays [9]. Individual assays differ in LLOD (CAP/CTM version 2.0 = 15 IU/mL; ART = 12 IU/mL) and assay design [7,15,16]. A recent study by Peiffer et al.…”

Section: Discussionmentioning

confidence: 99%

“…Several studies have evaluated different HCV RNA detection assays to determine if the increased sensitivity of the lower limit of detection (LLOD) of different assays has more impact on clinical treatment. Two new assays, COBAS Ampliprep/COBAS TaqMan (CAP/CTM; Roche Molecular Systems, Pleasanton, CA, USA) HCV Test version 2.0 (LLOD, 15 IU/mL) and Abbott RealTime (ART; Abbott Molecular, Abbott Park, IL, USA) HCV (LLOD, 12 IU/mL), that are commonly used in clinical practice reportedly have similar sensitivities [7].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Rapid virological response assessment by Abbott RealTime hepatitis C virus assay for predicting sustained virological responses in patients with hepatitis C virus genotype 1 treated with pegylated‐interferon and ribavirin

Yen

Hsu

et al. 2016

The Kaohsiung J of Med Scie

View full text Add to dashboard Cite

The lower limits of virus detection of hepatitis C virus (HCV) RNA detection assays are continuously improving. We aimed to assess the utility of more precise definition of 4(th) week viral load [rapid virological response (RVR)] in predicting sustained virological response (SVR) in HCV genotype 1 patients treated with pegylated-interferon (PEG-IFN) and ribavirin. Clinical data of treatment-naïve HCV genotype 1 patients were retrospectively collected from 2009 to 2014. Patients were grouped according to 4(th) week viral load as follows: undetectable (n = 90) and detectable but not quantifiable (< 12 IU/mL, n = 27). All patients received PEG-IFNα-2a or -2b and ribavirin for 24 weeks. Serum HCV RNA levels were measured by Abbott RealTime (ART; Abbott Molecular, Abbott Park, IL, USA) HCV assay. SVR was 95.5% and 63% in the undetectable group and < 12 IU/mL group of 4(th) week viral load, respectively. The between-group difference in SVR was significant (p < 0.001). We determined 4(th) week viral load was independently associated with SVR (odds ratio = 19.28; p = 0.002) and a good predictor of SVR [area under the curve (AUC) = 0.775; p = 0.001]. ART HCV assays had a stronger SVR predictive value in HCV genotype 1 patients, indicating that only the undetectable group of 4(th) week viral load patients measured by ART HCV assay should be considered for shorter treatment time (24 weeks) with PEG-IFN and ribavirin.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Rapid virological response assessment by Abbott RealTime hepatitis C virus assay for predicting sustained virological responses in patients with hepatitis C virus genotype 1 treated with pegylated‐interferon and ribavirin

Yen

Hsu

et al. 2016

The Kaohsiung J of Med Scie

View full text Add to dashboard Cite

show abstract

Three-dimensional NiCo2O4 nanowires encapsulated in nitrogen-doped carbon networks as a high-performance aptamer stabilizer for impedimetric ultrasensitive detection of hepatitis C virus core antigen

Rahmati

Roushani

Hosseini

2021

Surfaces and Interfaces

View full text Add to dashboard Cite

Differences between quantification of genotype 3 hepatitis C virus RNA by Versions 1.0 and 2.0 of the COBAS AmpliPrep/COBAS TaqMan HCV Test

Pierce

Tran

Rosenberg

2017

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

Background:Differences between the designs of hepatitis C virus (HCV) viral load assays can result in genotype-related variability in RNA quantification. We tested paired aliquots of plasma specimens from HCV-infected individuals using two versions (v1.0 and v2.0) of the Roche COBAS AmpliPrep/COBAS TaqMan HCV Test (CAP/CTM HCV) and noted variability between results for a subset of specimens; we then sought to determine whether discrepant results were more prevalent among specific HCV genotypes.Methods:Archived and prospectively-collected plasma samples from 114 unique patients were tested using CAP/CTM HCV v1.0 and v2.0. The HCV genotype result for each patient was determined by retrospectively reviewing laboratory records.Results:All (46/46) specimens with quantifiable viral loads from patients with genotype 1 or 2 infection had CAP/CTM HCV v1.0 and v2.0 results that were within 0.5 logConclusions:In patients infected with HCV genotype 3, sequential CAP/CTM HCV viral load results should be compared with caution and interpreted in the context of the specific assay version used.

show abstract

Estimation of two real-time RT-PCR assays for quantitation of hepatitis C virus RNA during PEG-IFN plus ribavirin therapy by HCV genotypes and IL28B genotype

Cited by 3 publications

References 19 publications

Rapid virological response assessment by Abbott RealTime hepatitis C virus assay for predicting sustained virological responses in patients with hepatitis C virus genotype 1 treated with pegylated‐interferon and ribavirin

Rapid virological response assessment by Abbott RealTime hepatitis C virus assay for predicting sustained virological responses in patients with hepatitis C virus genotype 1 treated with pegylated‐interferon and ribavirin

Three-dimensional NiCo2O4 nanowires encapsulated in nitrogen-doped carbon networks as a high-performance aptamer stabilizer for impedimetric ultrasensitive detection of hepatitis C virus core antigen

Differences between quantification of genotype 3 hepatitis C virus RNA by Versions 1.0 and 2.0 of the COBAS AmpliPrep/COBAS TaqMan HCV Test

Contact Info

Product

Resources

About